SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Elevance Health Inc. (ELV) trades at a trailing P/E of 12.4, forward P/E of 12.1. Trailing earnings yield is 8.03%, forward earnings yield 8.26%. PEG 3.90. Graham Number is $337.65.
Criteria proven by this page:
- VALUE (69/100, Pass) — P/E is below market average (12.4); analyst target implies upside (+22.1%); earnings yield beats bond yields (8.03%).
- Forward P/E 12.1 (down from trailing 12.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 3.90 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 8.03% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 8.26% as earnings recover.
- Analyst consensus target $382.64 (+22.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 62/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
69/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ELV
Valuation Multiples
P/E (TTM)12.4
Forward P/E12.1
PEG Ratio3.90
Forward PEG3.90
P/B Ratio1.61
P/S Ratio0.35
EV/EBITDA9.7
Per Share Data
EPS (TTM)$25.53
Forward EPS (Est.)$25.89
Book Value / Share$198.49
Revenue / Share$897.77
FCF / Share$14.31
Yields & Fair Value
Earnings Yield8.03%
Forward Earnings Yield8.26%
Dividend Yield2.16%
Graham Number$337.65
SharesGrow IV$848.27 (+170.7%)
Analyst Target$382.64 (+22.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
15.4 |
-4.39 |
1.51 |
0.45 |
1.80% |
| 2017 |
15.0 |
0.27 |
2.17 |
0.64 |
1.22% |
| 2018 |
17.8 |
-15.40 |
2.34 |
0.73 |
1.16% |
| 2019 |
16.1 |
0.54 |
2.43 |
0.74 |
1.06% |
| 2020 |
17.6 |
-5.71 |
2.43 |
0.66 |
1.18% |
| 2021 |
18.5 |
0.48 |
3.13 |
0.82 |
0.98% |
| 2022 |
20.9 |
-7.64 |
3.40 |
0.79 |
1.00% |
| 2023 |
18.4 |
5.50 |
2.80 |
0.64 |
1.27% |
| 2024 |
14.4 |
8.48 |
2.08 |
0.49 |
1.76% |
| 2025 |
13.7 |
-5.63 |
1.77 |
0.39 |
1.97% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$9.21 |
$84.98B |
$2.47B |
2.9% |
| 2017 |
$14.35 |
$90.04B |
$3.84B |
4.3% |
| 2018 |
$14.19 |
$92.11B |
$3.75B |
4.1% |
| 2019 |
$18.47 |
$104.21B |
$4.81B |
4.6% |
| 2020 |
$17.98 |
$121.87B |
$4.57B |
3.8% |
| 2021 |
$24.73 |
$138.64B |
$6.1B |
4.4% |
| 2022 |
$24.28 |
$156.6B |
$5.89B |
3.8% |
| 2023 |
$25.22 |
$171.34B |
$5.99B |
3.5% |
| 2024 |
$25.68 |
$176.81B |
$5.98B |
3.4% |
| 2025 |
$25.12 |
$199.13B |
$5.66B |
2.8% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$25.86 |
$25.43 – $27.38 |
$193.05B |
$183.52B – $218.07B |
16 |
| 2027 |
$29.03 |
$28.17 – $31.25 |
$197.1B |
$190.26B – $209.88B |
14 |
| 2028 |
$34.43 |
$32.88 – $37.40 |
$208.24B |
$208.1B – $208.38B |
4 |
| 2029 |
$43.72 |
$41.81 – $48.10 |
$219.95B |
$212.53B – $236.87B |
2 |
| 2030 |
$46.13 |
$44.11 – $50.74 |
$229.5B |
$221.77B – $247.16B |
2 |
